Ordering
Available Variants1 g
CHA.54810-1g
Price
€30.32
Available – Dispatch in 14 days
5 g
CHA.54810-5g
Price
€100.80
Available – Dispatch in 14 days
25 g
CHA.54810-25g
Price
€417.60
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
1 g | CHA.54810-1g | €30.32 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 g | CHA.54810-5g | €100.80 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 g | CHA.54810-25g | €417.60 |
≥99% (TLC), powder, β-adrenoceptor antagonist
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C16H21NO2 · HCl |
|---|---|
| CAS Number | 318-98-9 |
| Molecular Weight | 295.80 |
| NACRES | NA.77 |
| PubChem Substance ID | 24277796 |
| UNSPSC Code | 12352200 |
| EC Number | 206-268-7 |
| MDL number | MFCD00012558 |
| Beilstein/REAXYS Number | 4164259 |
| Assay | ≥99% (TLC) |
| Form | powder |
| Quality level | 200 |
Safety Information Handling visibility
| pictograms |
GHS07
 GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H302 |
| pcodes | P264 - P270 - P301 + P312 + P330 - P501 |
| Hazard Classifications | Acute Tox. 4 Oral |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | dust mask type N95 (US), Eyeshields, Faceshields, Gloves |
Technical Overview & Applications Use-case context
(±)-Propranolol hydrochloride, with a CAS number of 3506-09-0, is a non-selective beta-adrenergic receptor blocker commonly utilized in the management of various cardiovascular conditions, including hypertension, angina, and arrhythmias. Its mechanism of action involves the competitive inhibition of beta-1 and beta-2 adrenergic receptors, resulting in decreased heart rate, contractility, and cardiac output. As a hydrochloride salt, it exhibits improved aqueous solubility, facilitating its formulation into various pharmaceutical preparations. The compounds pharmacokinetic profile is characterized by extensive hepatic first-pass metabolism, with its bioavailability being significantly influenced by factors such as dosage and individual patient characteristics. Due to its efficacy and relatively well-tolerated side effect profile, (±)-Propranolol hydrochloride remains a widely prescribed medication in the treatment of cardiovascular diseases. Its therapeutic applications continue to be a subject of ongoing research and clinical evaluation.
